SpineThera is pleased to announce its participation at The Great State of Pharmaceuticals & Biotechnology 2017 conference to be held on August 1st, 2017 in St. Louis Park, MN.
Emily Meyering, Director of R&D, will give a company presentation at 1:15 pm as part of the conference Company Showcase series. The Company Showcase series includes 3 companies from Minnesota’s Medical Alley invited to present their biotechnology to the conference.
Jeff Missling, CEO, will participate in a panel discussion at 3:50 pm titled “Case Studies of Non-Dilutive Financing in Emerging BioPharma Ventures”. SpineThera has been awarded $2.34M in non-dilutive funding from 4 government sources.
More information about the conference can be found at the Great State of Pharmaceuticals & Biotechnology 2017 website.
SpineThera designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug.
About the event:
The Great State of Pharmaceuticals & Biotechnology 2017 brings Medical Alley’s drug industry together for a day of learning, networking, and fellowship. The conference will feature exceptional industry content and the opportunity to connect with suppliers, consultants and peers to fuel the connectivity of your Medical Alley community. It’s a trade fair, a conference, an exhibition and peer networking event.